NovaBay Pharmaceuticals (NBY) Competitors $0.65 -0.02 (-3.61%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock NBY vs. ALLR, MTEX, ATHA, FLGC, EDSA, LEXX, HOOK, NEUP, ERNA, and SYBXShould you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include Allarity Therapeutics (ALLR), Mannatech (MTEX), Athira Pharma (ATHA), Flora Growth (FLGC), Edesa Biotech (EDSA), Lexaria Bioscience (LEXX), HOOKIPA Pharma (HOOK), Neuphoria Therapeutics (NEUP), Ernexa Therapeutics (ERNA), and Synlogic (SYBX). These companies are all part of the "pharmaceutical products" industry. NovaBay Pharmaceuticals vs. Its Competitors Allarity Therapeutics Mannatech Athira Pharma Flora Growth Edesa Biotech Lexaria Bioscience HOOKIPA Pharma Neuphoria Therapeutics Ernexa Therapeutics Synlogic Allarity Therapeutics (NASDAQ:ALLR) and NovaBay Pharmaceuticals (NYSE:NBY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends. Which has higher earnings and valuation, ALLR or NBY? NovaBay Pharmaceuticals has higher revenue and earnings than Allarity Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllarity TherapeuticsN/AN/A-$24.51MN/AN/ANovaBay Pharmaceuticals$9.78M0.38-$9.64M-$53.72-0.01 Do insiders & institutionals believe in ALLR or NBY? 11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are held by institutional investors. 0.0% of Allarity Therapeutics shares are held by insiders. Comparatively, 0.1% of NovaBay Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, ALLR or NBY? Allarity Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Do analysts rate ALLR or NBY? NovaBay Pharmaceuticals has a consensus price target of $0.85, indicating a potential upside of 31.62%. Given NovaBay Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NovaBay Pharmaceuticals is more favorable than Allarity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NovaBay Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ALLR or NBY more profitable? Allarity Therapeutics has a net margin of 0.00% compared to NovaBay Pharmaceuticals' net margin of -102.72%. Allarity Therapeutics' return on equity of -147.94% beat NovaBay Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Allarity TherapeuticsN/A -147.94% -90.33% NovaBay Pharmaceuticals -102.72%-7,293.78%-158.41% Does the media favor ALLR or NBY? In the previous week, Allarity Therapeutics had 4 more articles in the media than NovaBay Pharmaceuticals. MarketBeat recorded 4 mentions for Allarity Therapeutics and 0 mentions for NovaBay Pharmaceuticals. Allarity Therapeutics' average media sentiment score of 0.76 beat NovaBay Pharmaceuticals' score of 0.00 indicating that Allarity Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Allarity Therapeutics Positive NovaBay Pharmaceuticals Neutral SummaryNovaBay Pharmaceuticals beats Allarity Therapeutics on 8 of the 13 factors compared between the two stocks. Get NovaBay Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBY vs. The Competition Export to ExcelMetricNovaBay PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.76M$752.17M$5.57B$20.65BDividend YieldN/A4.84%4.23%3.65%P/E Ratio-0.011.4328.6127.29Price / Sales0.3825.51412.0053.17Price / CashN/A19.5636.0222.28Price / Book0.156.608.234.60Net Income-$9.64M-$4.53M$3.23B$995.22M7 Day Performance-0.55%1.40%-0.01%-0.80%1 Month Performance7.63%1.30%5.61%3.55%1 Year Performance-69.82%3.42%26.52%7.35% NovaBay Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBYNovaBay Pharmaceuticals1.5826 of 5 stars$0.65-3.6%$0.85+31.6%-69.0%$3.76M$9.78M-0.0130ALLRAllarity Therapeutics0.5759 of 5 stars$1.05+4.0%N/A-83.1%$15.83MN/A0.0010News CoverageMTEXMannatech1.3774 of 5 stars$8.31-2.2%N/A+14.8%$15.80M$117.87M-83.14250ATHAAthira Pharma3.4579 of 5 stars$0.40-7.5%$11.25+2,696.4%-88.2%$15.71MN/A-0.1940Positive NewsFLGCFlora Growth2.6145 of 5 stars$0.69+0.6%$4.00+480.6%-39.9%$15.55M$53.26M-0.70280Positive NewsEDSAEdesa Biotech2.2463 of 5 stars$2.20+5.3%$5.00+127.3%-48.5%$15.44MN/A-1.3820Positive NewsGap UpLEXXLexaria Bioscience1.95 of 5 stars$0.83-5.3%$5.00+499.4%-72.0%$14.65M$460K-1.417HOOKHOOKIPA Pharma3.0496 of 5 stars$1.20+0.8%$4.50+275.0%-80.2%$14.63M$43.95M-0.21160NEUPNeuphoria Therapeutics2.215 of 5 stars$7.70+0.1%$21.00+172.7%N/A$14.48M$15.66M0.00N/AERNAErnexa Therapeutics0.5651 of 5 stars$1.96+0.5%N/A-93.9%$14.44M$535K-0.2410Gap UpSYBXSynlogic1.1585 of 5 stars$1.23+1.2%N/A-14.3%$14.33M$10K-0.4980Positive NewsGap Up Related Companies and Tools Related Companies ALLR Alternatives MTEX Alternatives ATHA Alternatives FLGC Alternatives EDSA Alternatives LEXX Alternatives HOOK Alternatives NEUP Alternatives ERNA Alternatives SYBX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NBY) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovaBay Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBY Stock Alerts